Molecular targeting of glioblastoma: Drug discovery and therapies

Trends in Molecular Medicine

Volumn 17, Issue 6, 2011, Pages 301-312

  Bai, Ren Yuan ^a   Staedtke, Verena ^a   Riggins, Gregory J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CETUXIMAB; CILENGITIDE; DASATINIB; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; INIPARIB; LAPATINIB; NIMOTUZUMAB; PAZOPANIB; PROTEIN TYROSINE KINASE; RAPAMYCIN; RILOTUMUMAB; SORAFENIB; SUNITINIB; TANDUTINIB; TEMSIROLIMUS; TORICEL; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB; VELIPARIB;

CLINICAL TRIAL (TOPIC); CONCENTRATION (PARAMETERS); DRUG SCREENING; GENE MUTATION; GENOMICS; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG EVALUATION; DRUG RESISTANCE, NEOPLASM; GENOMICS; GLIOBLASTOMA; HUMANS; MICE; MODELS, BIOLOGICAL; RATS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79958766637     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.01.011     Document Type: Review

References (119)

1. Khasraw M., Lassman A.B. Advances in the treatment of malignant gliomas. Curr. Oncol. Rep. 2010, 12:26-33.
2. Nobusawa S., et al. Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol. 2010, 20:936-944.
3. Harada K., et al. Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. Cancer Res. 1998, 58:4694-4700.
4. Walker C., et al. Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity. Clin. Cancer Res. 2003, 9:4841-4851.
5. Nishikawa R., et al. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol. 2004, 21:53-56.
6. Jeuken J., et al. Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol. 2009, 19:661-671.
7. Denysenko T., et al. Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies. Cell Biochem. Funct. 2010, 28:343-351.
8. van den Bent M.J., et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 2009, 27:1268-1274.
9. Sarin H. Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J. Transl. Med. 2009, 7:77.
10. Druker B.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344:1031-1037.
11. Pope W.B., Itagaki M.W. Characterizing brain tumor research: the role of the National Institutes of Health. Am. J. Neuroradiol. 2010, 31:605-609.
12. Parsons D.W., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
13. Velculescu V.E., et al. Serial analysis of gene expression. Science 1995, 270:484-487.
14. Boon K., et al. An anatomy of normal and malignant gene expression. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11287-11292.
15. Rao S.K., et al. A survey of glioblastoma genomic amplifications and deletions. J. Neurooncol. 2010, 96:169-179.
16. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
17. Papeo G., et al. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?. Expert Opin. Ther. Pat. 2009, 19:1377-1400.
18. Jensen R.L. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J. Neurooncol. 2009, 92:317-335.
19. Barcellos-Hoff M.H., et al. Therapeutic targets in malignant glioblastoma microenvironment. Semin. Radiat. Oncol. 2009, 19:163-170.
20. Wong A.J., et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:2965-2969.
21. Chico L.K., et al. Targeting protein kinases in central nervous system disorders. Nat. Rev. Drug Discov. 2009, 8:892-909.
22. Hobbs S.K., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:4607-4612.
23. Sarin H., et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J. Transl. Med. 2009, 7:51-64.
24. Newton H.B. Advances in strategies to improve drug delivery to brain tumors. Expert Rev. Neurother. 2006, 6:1495-1509.
25. Chen Z.G. Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol. Med. 2010, 16:594-602.
26. Strausberg R.L., et al. Oncogenomics and the development of new cancer therapies. Nature 2004, 429:469-474.
27. Samuels Y., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7:561-573.
28. Gallia G.L., et al. Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol. Cancer Ther. 2009, 8:386-393.
29. Trembath D.G., et al. A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII. Mol. Cancer 2007, 6:30-43.
30. Sur S., et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3964-3969.
31. Danovi D., et al. Imaging-based chemical screens using normal and glioma-derived neural stem cells. Biochem. Soc. Trans. 2010, 38:1067-1071.
32. Heidner G.L., et al. Analysis of survival in a retrospective study of 86 dogs with brain tumors. J. Vet. Intern. Med. 1991, 5:219-226.
33. Candolfi M., et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J. Neurooncol. 2007, 85:133-148.
34. Fomchenko E.I., Holland E.C. Mouse models of brain tumors and their applications in preclinical trials. Clin. Cancer Res. 2006, 12:5288-5297.
35. de Vries N.A., et al. High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treat. Rev. 2009, 35:714-723.
36. Barth R.F., Kaur B. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J. Neurooncol. 2009, 94:299-312.
37. Schlegel J., et al. The p16/Cdkn2a/Ink4a gene is frequently deleted in nitrosourea-induced rat glial tumors. Pathobiology 1999, 67:202-206.
38. Sibenaller Z.A., et al. Genetic characterization of commonly used glioma cell lines in the rat animal model system. Neurosurg. Focus 2005, 19:E1.
39. Clavreul A., et al. Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model. J. Neurooncol. 2006, 79:9-17.
40. Mathieu D., et al. Standardization and detailed characterization of the syngeneic Fischer/F98 glioma model. Can. J. Neurol. Sci. 2007, 34:296-306.
41. Schmidek H.H., et al. Morphological studies of rat brain tumors induced by N-nitrosomethylurea. J. Neurosurg. 1971, 34:335-340.
42. Guo P., et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol. 2003, 162:1083-1093.
43. Parsa A.T., et al. Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy. Neurosurgery 2000, 47:993-999. discussion 999-1000.
44. Benda P., et al. Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J. Neurosurg. 1971, 34:310-323.
45. Asai A., et al. Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J. Neurooncol. 1994, 19:259-268.
46. Ausman J.I., et al. Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res. 1970, 30:2394-2400.
47. Szatmari T., et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 2006, 97:546-553.
48. Pandita A., et al. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 2004, 39:29-36.
49. Shu Q., et al. Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells 2008, 26:1414-1424.
50. Lee J., et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403.
51. Siu I.M., et al. Establishment of a human glioblastoma stemlike brainstem rodent tumor model. J. Neurosurg. Pediatr. 2010, 6:92-97.
52. Fulop G.M., Phillips R.A. The scid mutation in mice causes a general defect in DNA repair. Nature 1990, 347:479-482.
53. Stupp R., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
54. Attenello F.J., et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann. Surg. Oncol. 2008, 15:2887-2893.
55. Norden A.D., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70:779-787.
56. Vredenburgh J.J., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 2007, 25:4722-4729.
57. Zuniga R.M., et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. 2009, 91:329-336.
58. Kreisl T.N., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 2009, 27:740-745.
59. Friedman H.S., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009, 27:4733-4740.
60. Raizer J.J., et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010, 116:5297-5305.
61. Lamborn K.R., et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008, 10:162-170.
62. Iwamoto F.M., et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009, 73:1200-1206.
63. Quant E.C., et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 2009, 11:550-555.
64. de Groot J.F., et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010, 12:233-242.
65. Narayana A., et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol. 2010, 12:985-990.
66. Gerstner E.R., et al. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010, 12:466-472.
67. Miletic H., et al. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin. Ther. Targets 2009, 13:455-468.
68. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
69. Batchelor T.T., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
70. de Groot J.F., et al. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J. Neurooncol. 2008, 90:89-97.
71. Sathornsumetee S., et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010, 12:1300-1310.
72. Lai A., et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 2011, 29:142-148.
73. Stupp R., Weller M. 2010: neuro-oncology is moving!. Curr. Opin. Neurol. 2010, 23:553-555.
74. Lang F.F., et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol. 2003, 21:2508-2518.
75. Stommel J.M., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318:287-290.
76. Stupp R., et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 2010, 28:2712-2718.
77. Weller M., et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat. Rev. Neurol. 2010, 6:39-51.
78. Leary R.J., et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci. Transl. Med. 2010, 2:20ra14.
79. Singh S.K., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
80. Bao S., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
81. Levine A.J., Puzio-Kuter A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344.
82. Dang L., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
83. Seltzer M.J., et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010, 70:8981-8987.
84. Senderowicz A.M. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer. Clin. Cancer Res. 2010, 16:1719-1725.
85. Sarapa N. Exploratory IND: a new regulatory strategy for early clinical drug development in the United States. Ernst. Schering Res. Found Workshop 2007, 59:151-163.
86. Brown P.D., et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol. 2008, 26:5603-5609.
87. Reardon D.A., et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol. 2010, 96:219-230.
88. Rich J.N., et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 2004, 22:133-142.
89. Franceschi E., et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br. J. Cancer 2007, 96:1047-1051.
90. Kreisl T.N., et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J. Neurooncol. 2009, 92:99-105.
91. Thiessen B., et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother. Pharmacol. 2009, 65:353-361.
92. Hainsworth J.D., et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 2010, 116:3663-3669.
93. Reardon D.A., et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J. Neurooncol. 2011, 101:57-66.
94. Du J., et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat. Biotechnol. 2009, 27:77-83.
95. Ramakrishnan M.S., et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009, 1:41-48.
96. Ramos T.C., et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol. Ther. 2006, 5:375-379.
97. Belda-Iniesta C., et al. Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol. Ther. 2006, 5:912-914.
98. Hasselbalch B., et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol. 2010, 12:508-516.
99. Jun H.T., et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin. Cancer Res. 2007, 13:6735-6742.
100. Reardon D.A., et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br. J. Cancer 2009, 101:1995-2004.
101. Dresemann G., et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J. Neurooncol. 2010, 96:393-402.
102. Wen P.Y., et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin. Cancer Res. 2006, 12:4899-4907.
103. Razis E., et al. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin. Cancer Res. 2009, 15:6258-6266.
104. Reardon D.A., et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol. 2005, 23:9359-9368.
105. Wick W., et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 2010, 28:1168-1174.
106. Kreisl T.N., et al. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol. 2010, 12:181-189.
107. Akhavan D., et al. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol. 2010, 12:882-889.
108. Galanis E., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 2005, 23:5294-5304.
109. Chang S.M., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 2005, 23:357-361.
110. Phuphanich S., et al. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J. Neurooncol. 2010, 100:95-103.
111. Kubicek G.J., et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74:433-439.
112. Reardon D.A., et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 2008, 26:5610-5617.
113. Chi A.S., et al. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 2009, 6:513-526.
114. Huang T.T., et al. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 2009, 6:500-512.
115. Reardon D.A., et al. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 2009, 115:2188-2198.
116. Brandes A.A., et al. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur. J. Cancer 2010, 46:348-354.
117. Iwamoto F.M., et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010, 12:855-861.
118. Drappatz J., et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78:85-90.
119. Gomez-Manzano C., et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol. 2008, 10:940-945.